Passive administration of monoclonal antibodies to Anthrolysin O prolong survival in mice lethally infected with Bacillus anthracis

[1]  R. Titball,et al.  Immunisation with anthrolysin O or a genetic toxoid protects against challenge with the toxin but not against Bacillus anthracis. , 2007, Vaccine.

[2]  P. Hanna,et al.  Bacillus anthracis anthrolysin O and three phospholipases C are functionally redundant in a murine model of inhalation anthrax. , 2007, FEMS microbiology letters.

[3]  Leonard A. Smith,et al.  Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display. , 2007, Journal of molecular biology.

[4]  Robert B. Mandell,et al.  Human Monoclonal Antibodies Directed against Toxins A and B Prevent Clostridium difficile-Induced Mortality in Hamsters , 2006, Infection and Immunity.

[5]  R. Rest,et al.  The Bacillus anthracis cholesterol-dependent cytolysin, Anthrolysin O, kills human neutrophils, monocytes and macrophages , 2006, BMC Microbiology.

[6]  A. Casadevall,et al.  Estimating the Relative Contributions of Virulence Factors for Pathogenic Microbes , 2006, Infection and Immunity.

[7]  A. Casadevall,et al.  Coping with Multiple Virulence Factors: Which Is Most Important? , 2005, PLoS pathogens.

[8]  M. Karin,et al.  Anthrolysin O and Other Gram-positive Cytolysins Are Toll-like Receptor 4 Agonists , 2004, The Journal of experimental medicine.

[9]  J. R. de los Toyos,et al.  Protection against Pneumococcal Pneumonia in Mice by Monoclonal Antibodies to Pneumolysin , 2004, Infection and Immunity.

[10]  T. Koehler,et al.  Characterization of Anthrolysin O, the Bacillus anthracis Cholesterol-Dependent Cytolysin , 2003, Infection and Immunity.

[11]  E. Unanue,et al.  Intracellular antibody neutralizes Listeria growth. , 2001, Immunity.

[12]  E. Unanue,et al.  Cutting edge: paradigm revisited: antibody provides resistance to Listeria infection. , 1999, Journal of immunology.

[13]  A. Casadevall,et al.  Epitope Location in the Cryptococcus neoformans Capsule Is a Determinant of Antibody Efficacy , 1997, The Journal of experimental medicine.

[14]  A. Casadevall,et al.  Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans , 1996, The Journal of experimental medicine.

[15]  D. Scheidegger,et al.  Production of monoclonal antibodies: strategy and tactics. , 1980, Journal of immunological methods.